Marc Philippe Stemmler

Marc Philippe Stemmler

Auto-generated profile, based on publicly available information

Marc Philippe Stemmler

Department of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2020 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
JYJing Yang
Jing Yang
PAParker Antin
Parker Antin
GBGeert Berx
Geert Berx
CBCédric Blanpain
Cédric Blanpain
TBThomas Brabletz
Thomas Brabletz
O(On behalf of the EMT International Association (TEMTIA)
On behalf of the EMT International Association (TEMTIA)
Epithelial–mesenchymal transition (EMT) encompasses dynamic changes in cellular organization from epithelial to mesenchymal phenotypes, which leads to functional changes in cell migration and invasion. EMT occurs in a diverse range of physiological and pathological conditions and is driven by a conserved set of inducing signals, transcriptional regulators and downstream effectors. With over 5,700 publications indexed by Web of Science in 2019 alone, research on EMT is expanding rapidly. This growing interest warrants the need for a consensus among researchers when referring to and undertaking research on EMT. This Consensus Statement, mediated by ‘the EMT International Association’ (TEMTIA), is the outcome of a 2-year-long discussion among EMT researchers and aims to both clarify the nomenclature and provide definitions and guidelines for EMT research in future publications. We trust that these guidelines will help to reduce misunderstanding and misinterpretation of research data generated in various experimental models and to promote cross-disciplinary collaboration to identify and address key open questions in this research field. While recognizing the importance of maintaining diversity in experimental approaches and conceptual frameworks, we emphasize that lasting contributions of EMT research to increasing our understanding of developmental processes and combatting cancer and other diseases depend on the adoption of a unified terminology to describe EMT.

30 August 2021 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SBSimone Brabletz
Simone Brabletz
HSHarald Schuhwerk
Harald Schuhwerk
TBThomas Brabletz
Thomas Brabletz
MSMarc P. Stemmler
Marc P. Stemmler
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

2 January 2019 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MSMarc P. Stemmler
Marc P. Stemmler
RERebecca L. Eccles
Rebecca L. Eccles
SBSimone Brabletz
Simone Brabletz
TBThomas Brabletz
Thomas Brabletz

15 July 2024 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
ASAnnemarie Schwab
Annemarie Schwab
ZRZhigang Rao
Zhigang Rao
jie zhangjie zhang
jie zhang
AGAndré Gollowitzer
André Gollowitzer
KSKatharina Siebenkäs
Katharina Siebenkäs
TBThomas Brabletz
Thomas Brabletz
Therapy resistance and metastasis, the most fatal steps in cancer, are often triggered by a (partial) activation of the epithelial–mesenchymal transition (EMT) programme. A mesenchymal phenotype predisposes to ferroptosis, a cell death pathway exerted by an iron and oxygen-radical-mediated peroxidation of phospholipids containing polyunsaturated fatty acids. We here show that various forms of EMT activation, including TGFβ stimulation and acquired therapy resistance, increase ferroptosis susceptibility in cancer cells, which depends on the EMT transcription factor Zeb1. We demonstrate that Zeb1 increases the ratio of phospholipids containing pro-ferroptotic polyunsaturated fatty acids over cyto-protective monounsaturated fatty acids by modulating the differential expression of the underlying crucial enzymes stearoyl-Co-A desaturase 1 (SCD), fatty acid synthase (FASN), fatty acid desaturase 2 (FADS2), elongation of very long-chain fatty acid 5 (ELOVL5) and long-chain acyl-CoA synthetase 4 (ACSL4). Pharmacological inhibition of selected lipogenic enzymes (SCD and FADS2) allows the manipulation of ferroptosis sensitivity preferentially in high-Zeb1-expressing cancer cells. Our data are of potential translational relevance and suggest a combination of ferroptosis activators and SCD inhibitors for the treatment of aggressive cancers expressing high Zeb1.

21 July 2020 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
NFNora Feldker
Nora Feldker
FFFulvia Ferrazzi
Fulvia Ferrazzi
HSHarald Schuhwerk
Harald Schuhwerk
SWSebastian A Widholz
Sebastian A Widholz
KGKerstin Guenther
Kerstin Guenther
SBSimone Brabletz
Simone Brabletz
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

16 June 2015 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
BPBogdan‐Tiberius Preca
Bogdan‐Tiberius Preca
Karolina Bajdak-RusinekKarolina Bajdak-Rusinek
Karolina Bajdak-Rusinek
KMKerstin Mock
Kerstin Mock
VSVignesh Sundararajan
Vignesh Sundararajan
JPJessica Pfannstiel
Jessica Pfannstiel
MSMarc P. Stemmler
Marc P. Stemmler
Invasion and metastasis of carcinomas are often activated by induction of aberrant epithelial–mesenchymal transition (EMT). This is mainly driven by the transcription factor ZEB1, promoting tumor‐initiating capacity correlated with increased expression of the putative stem cell marker CD44. However, the direct link between ZEB1, CD44 and tumourigenesis is still enigmatic. Remarkably, EMT‐induced repression of ESRP1 controls alternative splicing of CD44, causing a shift in the expression from the variant CD44v to the standard CD44s isoform. We analyzed whether CD44 and ZEB1 regulate each other and show that ZEB1 controls CD44s splicing by repression of ESRP1 in breast and pancreatic cancer. Intriguingly, CD44s itself activates the expression of ZEB1, resulting in a self‐sustaining ZEB1 and CD44s expression. Activation of this novel CD44s‐ZEB1 regulatory loop has functional impact on tumor cells, as evident by increased tumor‐sphere initiation capacity, drug‐resistance and tumor recurrence. In summary, we identified a self‐enforcing feedback loop that employs CD44s to activate ZEB1 expression. This renders tumor cell stemness independent of external stimuli, as ZEB1 downregulates ESRP1, further promoting CD44s isoform synthesis.